Not sure who needs to hear this but stock price and stock value aren't always the same. Often they're in the same range, but often there can be a big disconnect for a myriad of reasons.

The stock price of CYDY right now is about .50. I firmly believe, and many others believe, the stock value is much, much higher which is why we stay invested.

We base that value on the scientific data thus far and the promise of the MOA for other future indications. The rest of the world, which isn't paying attention to this OTC pre-revenue biotech, will eventually catch up, at which point the price will rise to match the intrinsic value. Big news such as a BTD, EUA, or stunning Topline report will wake the world up. You're ahead of the game because you've been following the story. You know the value is higher than .50, and if the market was rational it would probably be higher already.

But if anyone here believes the current value of CYDY is only .50 you should probably sell because you don't appear to know what you own.

Again, price doesn't always accurately reflect true value.

We know more about Leronlimab today than when it was trading at $10. More patients have been saved by the molecule, more patients lives have been extended by the drug, and more trial data has been gathered. Hence, the value is higher at a price of .50 whereas the value was lower when the price was at $10.